Analyst Price Target is $33.60
▲ +206.57% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Annovis Bio in the last 3 months. The average price target is $33.60, with a high forecast of $67.00 and a low forecast of $9.00. The average price target represents a 206.57% upside from the last price of $10.96.
Current Consensus is
Moderate Buy
The current consensus among 5 polled investment analysts is to moderate buy stock in Annovis Bio. This Moderate Buy consensus rating has held steady for over two years.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Read More